Ganirelix | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | |
Ganirelix | hsa00280 | Valine, leucine and isoleucine degradation | 4.31E-02 | 2 | P26440, Q02252 | IVD, ALDH6A1 | More | |
Ganirelix | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
Ganirelix | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
Ganirelix | hsa00750 | Vitamin B6 metabolism | 4.45E-02 | 1 | O00764 | PDXK | More | |
Ganirelix | hsa00860 | Porphyrin and chlorophyll metabolism | 5.29E-03 | 2 | P53004, P30043 | BLVRA, BLVRB | More | |
Ganirelix | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | |
Ganirelix | hsa01200 | Carbon metabolism | 4.06E-02 | 5 | P37837, O14521, P50213, P60891, Q02252 | TALDO1, SDHD, IDH3A, PRPS1, ALDH6A1 | More | |
Ganirelix | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | |
Ganirelix | hsa01522 | Endocrine resistance | 4.51E-02 | 2 | P04637, P42773 | TP53, CDKN2C | More | |
Ganirelix | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Ganirelix | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | |
Ganirelix | hsa03013 | RNA transport | 7.24E-03 | 11 | P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, O14602, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF1AY, EIF3A, EIF3J, RPP38, TACC3 | More | |
Ganirelix | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
Ganirelix | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
Ganirelix | hsa03450 | Non-homologous end-joining | 4.32E-02 | 1 | Q9NP87 | POLM | More | |
Ganirelix | hsa04015 | Rap1 signaling pathway | 9.14E-03 | 2 | P06213, O00522 | INSR, KRIT1 | More | |
Ganirelix | hsa04064 | NF-kappa B signaling pathway | 2.44E-02 | 4 | P10415, Q13546, Q9UDY8, Q13315 | BCL2, RIPK1, MALT1, ATM | More | |
Ganirelix | hsa04080 | Neuroactive ligand-receptor interaction | 4.15E-02 | 2 | Q01726, P41968 | MC1R, MC3R | More | |
Ganirelix | hsa04110 | Cell cycle | 2.75E-04 | 9 | P30260, P06493, O75293, P04637, P49918, P30304, P33981, P42773, P01106 | CDC27, CDK1, GADD45B, TP53, CDKN1C, CDC25A, TTK, CDKN2C, MYC | More | |
Ganirelix | hsa04115 | p53 signaling pathway | 2.54E-02 | 3 | O15151, Q13315, P10415 | MDM4, ATM, BCL2 | More | |
Ganirelix | hsa04141 | Protein processing in endoplasmic reticulum | 2.82E-04 | 8 | P18848, Q15437, Q15436, Q99941, P11142, P07900, Q9NR31, P14625 | ATF4, SEC23B, SEC23A, CREBL1, HSPA8, HSP90AA1, SAR1A, HSP90B1 | More | |
Ganirelix | hsa04145 | Phagosome | 4.79E-02 | 3 | P14598, Q13509, P68371 | NCF1, TUBB3, TUBB2C | More | |
Ganirelix | hsa04151 | PI3K-Akt signaling pathway | 5.85E-05 | 12 | P62753, P04637, P27348, P07900, P14625, Q16363, P22105, Q99941, P18848, Q96BR1, O00141, P56279 | RPS6, TP53, YWHAQ, HSP90AA1, HSP90B1, LAMA4, TNXB, CREBL1, ATF4, SGK3, SGK, TCL1A | More | |
Ganirelix | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ganirelix | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Ganirelix | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.46E-02 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Ganirelix | hsa04540 | Gap junction | 7.81E-03 | 3 | Q13509, P68371, Q9NRA1 | TUBB3, TUBB2C, PDGFC | More | |
Ganirelix | hsa04613 | Neutrophil extracellular trap formation | 9.53E-03 | 13 | P17252, O60603, P08246, Q9UM07, Q92769, Q6FI13, P14598, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, PADI4, HDAC2, H2AC18; H2AC19, NCF1, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Ganirelix | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
Ganirelix | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
Ganirelix | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Ganirelix | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | |
Ganirelix | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Ganirelix | hsa04912 | GnRH signaling pathway | 5.80E-03 | 7 | P17252, P51828, P18848, Q13557, Q16539, Q9Y6R4, Q14643 | PRKCA, ADCY7, ATF4, CAMK2D, MAPK14, MAP3K4, ITPR1 | More | |
Ganirelix | hsa04913 | Ovarian steroidogenesis | 2.52E-02 | 1 | P06213 | INSR | More | |
Ganirelix | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | |
Ganirelix | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | |
Ganirelix | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | |
Ganirelix | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
Ganirelix | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Ganirelix | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Ganirelix | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Ganirelix | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ganirelix | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
Ganirelix | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Ganirelix | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ganirelix | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
Ganirelix | hsa04972 | Pancreatic secretion | 3.86E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | |
Ganirelix | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
Ganirelix | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | |
Ganirelix | hsa05131 | Shigellosis | 1.80E-02 | 5 | Q13546, Q9UDY8, Q12778, Q13315, P10415 | RIPK1, MALT1, FOXO1, ATM, BCL2 | More | |
Ganirelix | hsa05132 | Salmonella infection | 4.85E-02 | 4 | Q13546, P10415, Q13509, P68371 | RIPK1, BCL2, TUBB3, TUBB2C | More | |
Ganirelix | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | |
Ganirelix | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | |
Ganirelix | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | |
Ganirelix | hsa05215 | Prostate cancer | 3.06E-03 | 5 | P10415, Q12778, P18848, Q9NRA1, P14625 | BCL2, FOXO1, ATF4, PDGFC, HSP90B1 | More | |
Ganirelix | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Ganirelix | hsa05222 | Small cell lung cancer | 4.26E-02 | 6 | P10826, Q13489, P10415, Q13077, O00463, P24522 | RARB, BIRC3, BCL2, TRAF1, TRAF5, GADD45A | More | |
Ganirelix | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Ganirelix | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
Ganirelix | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
Ganirelix | hsa05415 | Diabetic cardiomyopathy | 3.19E-02 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P14780 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, MMP9 | More | |